Zafgen Secures $45,000,000 Series E Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Broadway 8th Floor Cambridge, MA 02142
  • Company Description
    The company is developing novel therapeutics for the treatment of obesity.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    Proceeds from the financing will be used to support the continued development of beloranib, the Company’s obesity therapeutic. Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.
  • M&A Terms
  • Venture Investor
    RA Capital
  • Venture Investor
    Brookside Capital
  • Venture Investor
  • Venture Investor
    Alta Partners
  • Venture Investor

Trending on Xconomy